A resolutive therapy for Duchene muscular dystrophy, a severe degenerative disease of the skeletal muscle, is still lacking. Because autophagy has been shown to be crucial in clearing dysfunctional organelles and in preventing tissue damage, we investigated its pathogenic role and its suitability as a target for new therapeutic interventions in Duchenne muscular dystrophy (DMD). Here we demonstrate that autophagy is severely impaired in muscles from patients affected by DMD and mdx mice, a model of the disease, with accumulation of damaged organelles. The defect in autophagy was accompanied by persistent activation via phosphorylation of Akt, mammalian target of rapamycin (mTOR) and of the autophagy-inhibiting pathways dependent on them, including the translation-initiation factor 4E-binding protein 1 and the ribosomal protein S6, and downregulation of the autophagy-inducing genes LC3, Atg12, Gabarapl1 and Bnip3. The defective autophagy was rescued in mdx mice by long-term exposure to a low-protein diet. The treatment led to normalisation of Akt and mTOR signalling; it also reduced significantly muscle inflammation, fibrosis and myofibre damage, leading to recovery of muscle function. This study highlights novel pathogenic aspects of DMD and suggests autophagy as a new effective therapeutic target. The treatment we propose can be safely applied and immediately tested for efficacy in humans.
The therapeutic protocols currently in use, based on corticosteroid administration, provide some delay in the progression of the disease, but they are associated with severe side effects. 3, 4 Therapies that substitute corticosteroids or at least may act as corticosteroid-sparing drugs are thus being actively pursued, and biological mechanisms relevant to skeletal muscle homoeostasis are explored, in order to identify new targets.
Autophagy is emerging as an important process that limits muscle damage. 5, 6 Inhibition/alteration of autophagy contributes to myofibre degeneration leading to accumulation of abnormal organelles. 7, 8 Mutations that inactivate Jumpy, a phosphatase that counteracts the activation of VPS34 for autophagosome formation and reduces autophagy, are associated with a centronuclear myopathy. 9 This observation suggests that unbalanced autophagy is pathogenic in muscle degeneration. Likewise, hyperactivation of Akt as a consequence of muscle-specific deletion of the mammalian target of rapamycin (mTOR) leads to inhibition of autophagy and to a muscle phenotype resembling the one observed in muscular dystrophy. 10 The validity of autophagy modulation as a therapeutic strategy has been shown in a mouse model of Ulrich myopathy characterised by defective autophagy and accumulation of dysfunctional organelles. 11, 12 Forced reactivation of autophagy in these animals yielded a beneficial therapeutic response. 11 Indirect evidence indicates a possible role of deficient autophagy also in DMD pathogenesis. Higher levels of activation and phosphorylation of Akt are observed in muscles and primary myoblasts of the mdx mouse model of dystrophy. 13, 14 In agreement with this observation, the progressive muscular dystrophic phenotype observed in mdx mice is accompanied by progressively enhanced Akt activation especially at peak necrotic and hypertrophic phases of disease.
14 Such a phenotype has also been described in patients affected by DMD.
14 Akt is the most potent inhibitor of autophagy in skeletal muscle, blocking formation of autophagosomes and lysosomal-dependent degradation of their content, 15, 16 thereby suggesting a defective autophagic process. Moreover, histo-pathological hallmarks of DMD, namely protein aggregation, presence of swollen and damaged mitochondria, as well as distension of sarcoplasmic reticulum, are often observed when autophagy is impaired. 17, 18 The molecular pathways and the role of autophagy in DMD had not yet been investigated. We have now investigated the autophagic machinery in the mdx mouse model of DMD and in muscle tissues from DMD-affected patients. We found by in vivo and ex vivo analyses that autophagy is defective in both the human and mouse muscular dystrophy and that such defect contributes to the pathogenesis of the disease. Furthermore, we show that pharmacological reactivation of autophagy restores muscle structure and function. Our results identify autophagy as an important homoeostatic mechanism deranged in dystrophic muscles and indicate that novel therapeutic approaches aimed at reactivating autophagy are a valuable strategy to reduce muscle damage in DMD.
Results
Autophagy is reduced in mdx mice. To explore the status of autophagy in the dystrophic muscle, we compared key markers of autophagy in muscles from 4-month-old mdx and wild-type (WT) mice. We examined tibialis anterior (TA) and diaphragm muscles, because they are good examples of muscles relying on glycolytic and oxidative metabolism, 11 respectively, and closely mimic typical features of human muscular dystrophy, including myofibres with central nuclei and clustering of inflammatory cells. 13 As shown in Figure 1a , the levels of the lipidated form of the microtubule-associated protein-1 light chain 3 (LC3 II), which is generated during autophagosome formation and reflects active autophagy, 19 were significantly lower in muscles from mdx than in those of WT animals. The levels of p62, a protein known to be incorporated into autophagosomes and efficiently degraded, 20 were instead increased. We found enhanced levels of Akt in both TA and diaphragm muscles from mdx mice as already described. 13, 14 Of importance, we also found that phosphorylation of Akt on Ser473 was significantly increased as it was the phosphorylation of key downstream effectors of mTOR, namely the ribosomal protein S6 and the eukaryotic translation-initiation factor 4E-binding protein 1 (4E-BP1) (Figure 1b) . Phosphorylation of these proteins leads to their activation, which in muscle may lead to inhibition of autophagy. 21 Akt phosphorylation maintains mTOR in its active form and prevents FoxO3 translocation from the cytoplasm to the nucleus with ensuing transcriptional inhibition of genes essential to autophagosome formation. 12 In agreement with this, we found lower mRNA expression of autophagy-related genes directly regulated by FoxO3, that is, LC3, Atg12, Gabarapl1 and Bnip3 in mdx mouse muscles (Figure 3e ), indicating that FoxO3 downstream targets are impaired in Figure 1 Autophagy is defective in mdx mice. (a) Muscle homogenates from mdx and WT mice (60 mg per lane) were immunoblotted with antibodies against LC3 and p62. LC3 lipidation (LC3 II) in TA and in diaphragm muscles of mdx mice is reduced when compared with that of WT mice. The mdx mice also show accumulation of p62. Densitometric quantification of the LC3 II/I ratio and of p62, normalised against actin, is also shown. (b) In muscle homogenates (60 mg per lane), phosphorylation levels of Akt, S6 and 4E-BP1 are enhanced in mdx mice when compared with those of WT. We used the same protein extracts as in panel a. Densitometric analyses show the ratio between phosphorylated and corresponding total protein. In both panels, western blots are representative, and quantifications correspond to 15 animals per group. The asterisks indicate statistical significance versus WT (*Po0.05 and **Po0.01). Error bars represent S.E.M. mdx mice and providing a molecular correlate to the observed deficiency in autophagy.
Reduced autophagy in mdx mice is due to defective pro-autophagic signalling. Reduced LC3 II levels may depend on direct inhibition of autophagic flux; alternatively, they may be due to progressive exhaustion of LC3 II-containing vesicles following a hyperactivation of autophagy. To discriminate between these two possibilities, we used chloroquine, a lysosomal inhibitor that blocks the degradation of autophagosomes and their content, including of LC3 and p62. 22 Mice were treated with chloroquine, administered at the dose of 50 mg/kg body weight per day, for 7 days. This treatment led to significant increases in the levels of LC3 bands and p62 in both TA and diaphragm muscles of WT animals; such increases were not observed in the corresponding samples of mdx mice (Figures 2a and b) . These data indicate that the reduced LC3 II levels observed in mdx mouse muscles are not the consequence of vesicles exhaustion secondary to a hyperactive autophagic process.
We next subjected mice to short-term starvation (6 and 15 h of fasting), a treatment that activates autophagic signalling in different organs, including in muscles. 23 Starvation enhanced LC3 II levels with increased LC3 II/I ratio in TA and diaphragm muscles of WT mice; the levels of p62 were instead reduced, consistent with its enhanced degradation (Figures 3a and b and Supplementary Figure S1a Figure S1a) . Chloroquine enhanced the LC3 II/I ratio further and induced accumulation of p62 in muscles from WT animals, whereas it was completely ineffective in mdx mouse muscles (Figures 3a  and b) .
In agreement with these results, starvation decreased significantly phospho-Akt and phospho-4E-BP1 levels in WT animals ( Figures 3c and d and Supplementary Figure S1b) , where it also upregulated LC3B, Atg12, Bnip3 and Gabarapl1 mRNA levels (Figure 3e ), consistent with Akt and mTOR signalling inhibition and with autophagy induction.
No changes in protein phosphorylation or mRNA expression were instead observed in mdx mouse muscles after starvation, indicating a deficiency in pro-autophagic signalling (Figures 3c and e) .
We then analysed the ultrastructure of TA of WT and mdx mice in basal conditions (Figures 4a and c) . We detected defects neither in the architecture of the contractile apparatus nor in the mitochondrial pool of WT muscles ( Figure 4a and inset); in mdx mice, although the contractile apparatus seemed mostly unaffected (Figure 4c ), we observed an expansion of the cisternae of the endoplasmic reticulum in subsarcolemmal regions, where they occasionally form swollen stacks (Supplementary Figures S2a and b) ; this feature was even more prominent in starved mdx mice (Figure 4d ). Moreover, in tissues from mdx mice, infiltrating Autophagy reactivation improves the dystrophic phenotype of mdx mice. A specific dietary regimen, characterised by low amino-acid intake, but with the same caloric value of standard food was shown to ameliorate the dystrophic feature of Col6 À / À mice by enhancing in a chronic and physiological manner skeletal muscle autophagic machinery. 11, 12 We investigated whether a 3-month treatment with such a low-protein diet (LPD) reactivated autophagy in mdx mice and the impact of this effect on the dystrophic phenotype. LPD treatment enhanced expression of LC3 II and reduced that of p62 in TA and diaphragm not only in WT but also in mdx mice, with dephosphorylation, and thus inactivation, of Akt and 4E-BP1 (Figures 5a and b) . Consistently, we observed enhanced RNA levels of authopagic genes downstream to FoxO3 (Figure 5c and data not shown). Such an effect was not observed in mice treated with a control, standard diet (SD). Thus a long-term LPD was able to reactivate autophagy in mdx mice.
We then investigated the therapeutic efficacy of the LPD treatment. In LPD-treated mdx mice, the Whole Body Tension measurement, which determines the total phasic forward pulling tension exerted by the fore and hind limb muscles, 24, 25 was significantly improved as compared with SD-treated animals ( Figure 5c ). Histological analyses by the haematoxylin and eosin (H&E) staining revealed a degenerated muscle status in SD-treated mdx mice; in contrast, muscle architecture was nearly normal in LPD-treated mice, with a significantly lower number of necrotic myofibres (Figure 5d ). The beneficial effect of the diet was also apparent when the myofibre cross-sectional area (CSA) was investigated. The heterogeneity in myofibre CSA observed in SD-treated mdx mice, in which values ranged between 250 and 3000 mm 2 , with the largest diameters being a sign of degeneration (pathological hypertrophy) (Figure 5e ), was normalised in LPD-treated animals, with significantly more homogeneous frequency histograms and CSA values not significantly different from those observed in WT animals.
The percentage of apoptotic nuclei, measured using the TdT-mediated dUTP-biotin nick end labelling (TUNEL) method, was significantly lower in LPD-treated compared with SD-treated mdx mice, both in TA and diaphragm (Figure 6c ). This finding suggests that the treatment with LPD reduced also the programmed death of myofibres. Interestingly, LPD treatment in mdx mice increased also the number of centronucleated myofibres (Figure 5d ), indicating a benefit on muscle regeneration. Consistently, fibrosis and collagen accumulation was reduced in LPD-treated animals as assessed by the Masson's Trichrome staining (Figure 6a) .
Muscles of LPD-treated mdx mice showed an uptake of the Evans blue dye (EBD) injected i.v., which was significantly reduced with respect to that in SD-treated mice (Figure 6b ). Because EBD stains damaged myofibres, 26 this finding indicates that the treatment reduced the fragility of sarcolemmas in mdx mice. 26 It is noteworthy that long-lasting induction of autophagy in WT led to minor muscle alterations, as previously demonstrated by others, 11 including the increase of apoptotic degeneration of the myofibres, shown by an increased number of TUNEL-positive nuclei (Figure 6c ). This was expected because previous studies have already demonstrated that excessive autophagy induction is detrimental for muscle homoeostasis in healthy conditions, further highlighting the importance of a balanced autophagic flux.
Autophagy is defective in human DMD patients. We assessed whether the defect in autophagy observed in mdx mice applied also to the human disease. We analysed muscle biopsies from five DMD-affected patients and four relative controls. All tissues from DMD patients showed significantly lower levels of LC3 II and significant accumulation of p62 with respect to tissues from the controls (Figure 7a ). In addition, they showed enhanced phosphorylation of Akt and of 4E-BP1 (Figure 7b ), indicating that the pathway affected in DMD patients is identical to the one observed in mdx mice leading to a multi step inhibition of autophagy.
Discussion
In this study, we report that autophagy is defective in DMD, that defects in autophagy contribute significantly to the pathology of DMD, and that pharmacological strategies that reactivate autophagy have beneficial effects that can be exploited in therapeutic perspective. Moreover, we characterise the signalling mechanisms involved in autophagic deficiency in DMD.
The defect in autophagy was demonstrated by biochemical and ultrastructural analyses. We found a significant reduction Autophagy reactivation is therapeutic in mdx mice C De Palma et al in LC3 II, the active, lipidated form of LC3, in muscles from both DMD patients and mdx mice. The reduction in LC3 II was accompanied by clear signs of impaired autophagy at the ultrastructural level, with enhanced presence of damaged organelles. The reduction in the autophagic flux was further confirmed by the increase in p62 levels. The impairment in autophagy in the mouse model could not be rescued by up to 15 h of fasting, a treatment known to stimulate autophagic signalling in other conditions. 23 Restoration of autophagy, leading to increased levels of LC3 II and reduced levels of p62, required instead a long-term (3 months) treatment with a potent autophagy-reactivating treatment (LPD). These findings suggest that the defect in autophagy is due to an overall deficiency in the autophagic machinery rather than to a simple inhibition of the signalling pathways that stimulate autophagy.
When we investigated the autophagic signalling pathways and their alteration in muscular dystrophy, we found that inhibition of autophagy depended on Akt activation, as shown by its persistent phosphorylation reversible upon autophagy reactivation. Although we cannot exclude the intervention of multiple mechanisms, such as lysosomal defects, we found that downstream of Akt both the mTOR and FoxO3 pathways were involved as shown by the persistent phosphorylation of 4E-BP1, and the downregulation of Atg12, Bnip3 and Gabarapl1 also reversed when autophagy was reactivated.
Although the role of FoxO3 signalling in autophagy in skeletal muscle has already been assessed and investigated fully, 15, 16 our observation of a significant involvement of mTOR signalling in autophagy is an unexpected finding. To date, the role of mTOR in muscle autophagy, investigated in conditions different from DMD, that is, muscle atrophy and fasting conditions, was reported to be minor. 15, 16, 27 Indeed, inhibition of mTOR by rapamycin or its downregulation by RNA-mediated silencing in those settings was insufficient to induce autophagosome formation 15, 16, 27 and only slightly increased protein breakdown. 16 The observation of a relevant role of mTOR in mdx mice suggests that autophagy in DMD has characteristics and molecular constrains unique with respect to autophagy in other pathophysiological condition of skeletal muscle. A possible explanation of this specificity resides in the specific features of DMD, and the role of mTOR in it. Dystrophic muscle is characterised by repeated cycles of degeneration/regeneration, with the presence of regenerating and hypertrophic fibres generated as a compensatory mechanism due at least in part to hyperactivation of Akt and mTOR. 13, 14 Although important, this functional compensation also leads to inhibition of autophagy.
The role of autophagy in DMD pathophysiology and its relevance as a therapeutic target was investigated in a longterm treatment of mdx mice with LPD. We evaluated carefully several unrelated markers of muscle function, damage and regeneration, and inflammatory responses. These markers were investigated using multiple different approaches in mdx mice after 3 months of treatment with the low protein or SDs. Our results clearly show that LPD treatment has therapeutic efficacy and ameliorates the dystrophic phenotype of mdx mice. Indeed, we observed a significant recovery of muscle function, as shown by the improvement of whole body tension, accompanied by reduced muscle fibrosis, decreased collagen deposition into the muscle, reduced apoptosis of the myofibres and reduced accumulation of damaged organelles. Furthermore, the treatment preserved the regenerating ability of muscle, assessed as an increased number of centronucleated myofibres and uniform CSA distribution. These latter results suggest in particular that LPD maintains the number and function of myogenic precursor cells. Autophagy has indeed been shown to have roles as promoter of stem cell maintenance and in a variety of cell differentiation processes, including in cellular reprogramming. 28 Our results are consistent with a similar role of autophagy also in myogenic precursor cells.
We cannot exclude that the beneficial effects of LPD treatment depend on mechanisms other than autophagy, for example, by increased muscle homoeostasis. 29 Altogether, however, our findings suggest that a proper autophagic flux contributes significantly to rescue the dystrophic phenotype and that stimulation of autophagy represents a new pharmacological strategy in DMD.
Our results contribute to explain recent findings about an amelioration of the dystrophic phenotype using the mTOR inhibitor. 30 Rapamycin, however, may not be an appropriate long-term treatment for human DMD, because it completely blocks muscle growth of regenerating myofibres 31, 32 and has intrinsic toxicity. Our results explain also why enhancement of autophagy by the AMP-activated protein kinase stimulating agent 5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside, tested specifically in the diaphragm of mdx mice, leads to muscle functional and structural improvement. 33 Although this compound may be developed further for clinical application in DMD, the efficacy in humans of the treatment we report here can be tested immediately and safely.
Several other compounds acting on the pathways different from autophagy are now being explored in novel therapeutic strategies for DMD. Among these exon skipping and stem cell approaches appear a significant step forward to resolutive therapy, although not yet developed to a sufficient level of efficacy, as the results of the last clinical trials indicate.
2,34-36 Classical pharmacological approaches based on drugs targeting inflammation, fibrosis, epigenetic DNA modifications and redox modifications are also being tested, with favourable perspectives. [37] [38] [39] [40] [41] [42] [43] [44] In this scenario, the therapeutic approach that we propose appears of significant value: although we do not expect an approach targeting only autophagy to be resolutive, it can be safely used in combination with cell and gene therapies and with the other drugs currently being explored for treatment of DMD. Thus, it can achieve a synergic effect and possibly lead to drugsparing regimes. In particular, in the case of steroids, a drugsparing regime may be of particular value limiting their adverse reactions, which appear to be severe in approximately a third of the treated patients. 45 In conclusion, this study demonstrates the existence of a defect in autophagy in human and mouse muscular dystrophy, and that a treatment restoring autophagy ameliorates the dystrophic phenotype. Inhibition of muscle damage and inflammation, as well as maintenance of muscle regenerative capacity, appears to account for the therapeutic effect of this treatment.
Materials and Methods
Animals and treatments. C57BL/6 WT mice (C57Bl10SnJ strain) were purchased from Charles River (Wilmington, MA, USA), mdx mice (C57Bl10-mdx strain) from Jackson (Bar Harbor, ME, USA) and treated in accordance with the European Community guidelines and with the approval of the Institutional Ethical Committee.
The mice were housed in an environmentally controlled room (23 1C, 12 h light-dark cycle) and provided food and water ad libitum. For specific experiments, groups of mice (15 animals per group) were fed with either SD or LPD (see Table 1 for its composition). For starvation experiments, chow was removed in the morning and mice (15 animals per group) were maintained for 6 or 15 h with no food but free access to water. In the experiments with chloroquine, mdx mice (15 animals per group) were subjected to intraperitoneal injection with chloroquine diphosphate (50 mg/kg body weight; Sigma-Aldrich, Milano, Italy) every 24 h for 7 days.
Human muscle sample. Normal and DMD muscle samples were obtained from the 'Bank of DNA, cell lines and nerve-muscle cardiac tissue' of the Neurological Unit of the Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico of Milan, which is part of the Telethon Genetic Biobank network of Italy.
In vivo functional tests. The Whole Body Tension procedure was used to determine the ability of mice to exert tension in a forward pulling manoeuvre that is elicited by stroking the tail. The Whole Body Tension reflects the maximal acute phasic force the mouse can achieve to escape a potentially harmful event. The tails of the mice (SD or LPD-fed) were connected to a Grass FT03 transducer (Astro-Med Industrial Park, West Warwick, RI, USA) with a 4.0 silk thread (one end of the thread being tied to the tail and the other end to the transducer). Each mouse was placed into a small tube constructed of a metal screen with a grid spacing of 2 mm. The mice entered the apparatus and exerted a small resting tension on the transducer. Forward pulling movements were elicited by a standardised stroke of the tail with serrated forceps, and the corresponding forward pulling tensions were recorded using a Grass Polyview recording system. Between 20 and 30 strokes of the tail, forward pulling tensions were generally recorded during each session. The Whole Body Tension was determined by dividing the average of the top 5 or top 10 forward pulling tensions, respectively, by the body weight.
Histology and immunohistochemistry. The animals were killed by cervical dislocation, and TA or diaphragm muscles were dissected and immediately frozen in liquid N2-cooled isopentane. For histological analyses, serial muscle sections were obtained and stained in H&E following standard procedures. 46 The number of necrotic and centronucleated fibres was counted and analysed using the public domain software MBF_ImageJ for Microscopy (http://www.macbiophotonics.ca/index.htm).
To measure CSA of individual myofibres, muscle sections were stained with an anti-Laminin A (L1293; Sigma-Aldrich) antibody. Laminin, a major component of the basal lamina, was detected using an appropriate secondary antibody, and nuclei were visualised with the DNA dye 4 0 ,6-diamidino-2-phenylindole (DAPI). Masson's Trichrome staining was used for identifying collagen inside the muscle tissue, following standard protocols. 40 Morphometry. Morphometric analyses were performed on sections collected from similar regions of each TA and diaphragm muscles. Two images were captured from each section and Image 1.63 (Scion Corporation, Frederick, MD, USA) was used to determine the CSA of 700-1.000 myofibres per section. 47 EBD injection. As a measure for membrane permeability, the vital dye EBD was used. In all, 50 ml/g body weight of a 5 mg/ml solution of EBD (Sigma-Aldrich) prepared in physiological saline was injected i.v. through the tail vein. Mice were killed 18 h after EBD injection.
Apoptosis assay. Apopotsis was assessed by the TUNEL method on 10-mm cryosections using an in situ apoptosis detection kit (DeadEnd Fluorometric TUNEL System; Promega, Milano, Italy), according to the manufacturer's protocol. Sections were counterstained with DAPI and mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA). The data were expressed as TUNEL index, calculated by counting the number of TUNEL-positive nuclei divided by the DAPI-positive nuclei. The TUNEL index was calculated from four random and non-overlapping fields.
Fluorescent and phase-contrast image acquisition and manipulation. Fluorescent and phase-contrast images were taken on microscopes (Leica DMI4000 B automated inverted microscope; lenses: HCX PL FLUOTAR Â 10/0.30, HI PLAN I Â 40/0.59 and HCX PL FLUOTAR Â 100/1.30). Images were acquired using a DFC490 digital colour camera (Leica Microscopy Systems, Heerbrugg, Switzerland) and the acquisition software LAS AF (Leica Microscopy Systems). Images were assembled in panels using Photoshop 7.0 (Abobe System Software, Dublin, Ireland).
Electron microscopy. For transmission electron microscopy (TEM) analysis, entire diaphragms and TA from WT and mdx mice were dissected after the killing and fixed for 1 h in a solution containing 4% paraformaldehyde and 0.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, immobilised on a Sylgard coated Petri dish to prevent muscular contraction. The muscles were rinsed in the same buffer and further dissected into smaller blocks (1 mm 3 ) that were subsequently processed for TEM as described elsewhere. 48 Briefly, the samples were postfixed with osmium tetroxide (2% in cacodylate buffer), rinsed, en bloc stained with 1% uranyl acetate in 20% ethanol, dehydrated and embedded in epoxy resin (Epon 812; Electron Microscopy Science, Hatfield, PA, USA) that was baked for 48 h at 67 1C. Thin sections were obtained with an ultramicrotome (Reichert Ultracut E and UC7; Leica Microsystems, Vienna, Austria), stained with uranyl acetate and lead citrate, and finally examined with a Philips CM10 TEM (FEI, Eindhoven, Germany).
Protein isolation and western blotting. Tissue samples from TA and diaphragm muscles were homogenised in a lysis buffer containing 20 mM Tris Á HCl (pH 7.4), 10 mM EGTA, 150 mM NaCl, 1% Triton X-100, 10% glycerol supplemented with a cocktail of protease and phosphatase inhibitors (Sigma, St. Louis, MO, USA). Samples were centrifuged at 1.000 Â g for 10 min at 4 1C to discard nuclei and cellular debris. Protein concentration was determined by the bicinchoninic acid assay (Pierce, Thermo Fisher Scientific, Rockford, IL, USA). Homogenates were separated by SDS-PAGE and proteins were transferred to nitrocellulose membranes (Amersham Pharmacia, Piscataway, NJ, USA). The membranes were probed using the following antibodies anti: phospho-AMPKa (Thr172) (2531), AMPKa (2532), 4E-BP1 (9644), phospho-4E-BP1 (Thr37 and Thr46) (2855), Akt (9272), phospho-Akt (Ser473) (9271), S6 (2317) and phospho-S6 (Ser240 and Ser244) (2215), all obtained from Cell Signaling Technology (Billerica, MA, USA). Antibodies to b-Actin (A5441), LC3 (L7543) and p62 (P0067) were from Sigma.
After immunostaining with the appropriate secondary horse radish peroxidaseconjugated goat anti-rabbit or anti-mouse antibodies (from Cell Signaling, Beverly, CA, USA, and Bio-Rad, Milano, Italy, respectively), bands were revealed using the Amersham ECL detection system (GE Healthcare, Fairfield, CT, USA) and quantified by densitometry using the public domain software MBF_ImageJ for Microscopy (http://www.macbiophotonics.ca/index.htm).
Real-time PCR. Tissue samples were homogenised, and RNA was extracted using the TRIzol protocol (Invitrogen, Carlsbad, CA, USA). After solubilisation in RNase-free water, first-strand cDNA was generated from 1 mg of total RNA using the ImProm-II Reverse Transcription System (Promega, Madison, WI, USA). Specific sets of primer pairs, described in Table 2 , were designed to hybridise to unique regions of the appropriate gene sequence. Real-time PCR was performed using the SYBR Green Supermix (Bio-Rad) on a Roche LightCycler 480 Instrument (Roche Diagnostics, Rotkreuz, Switzerland). All reactions were run as triplicates. Samples were analysed using the Roche LightCycler 480 Software (release 1.5.0) and the second derivative maximum method. The fold increase or decrease was determined relative to a control after normalising to the internal standard 36b4.
Statistical analyses. Values were expressed as means ± S.E.M. The statistical significance of the differences between means was assessed by independent Student's t-test or by one-way ANOVA followed by the Bonferroni post-test to determine which groups were significantly different from the others. A probability of o5% (Po0.05) was considered to be significant. The diets were designed as described previously. 
